Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gesves – page 57

942 clinical trials in Gesves, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gesves at a glance
942
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

942 trials in Gesves

Open in trial search

Study on WT1 mRNA DC Vaccine to Prevent Relapse in Adults with Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:WT1 mRNA DC
  • Sponsor:Antwerp University Hospital

Prostate cancer

Not recruiting

A Study of Cabazitaxel and Pelvic Radiation Therapy Combined with Hormone Treatment for Patients with High-Risk Localized Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Unicancer

Trial of Ataluren for Severe Common Variable Immunodeficiency with Autoimmunity in Patients with LRBA Deficiency

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ataluren
  • Sponsor:CHU De Liege

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Dostarlimab with CAPEOX and CAPEOX Alone for Patients with Untreated Stage III Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Xcovery Holding Co. LLC

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:DF1001
  • Sponsor:Dragonfly Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Effects and Safety of Buloxibutid for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buloxibutid
  • Sponsor:Vicore Pharma AB

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Neuroblastoma

Not recruiting

Study on Bevacizumab with Temozolomide and Irinotecan for Children with Relapsed or Refractory Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gesves

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on chronic rhinosinusitis treatment, specifically targeting patients with nasal polyps. Clinical investigations are evaluating novel therapeutic approaches using monoclonal antibodies to improve patient outcomes.

  • Nasal Polyp Management
  • Anti-IL-33 Therapy
  • Rhinosinusitis Treatment

The trials aim to assess new therapeutic options for patients with inadequately controlled symptoms, focusing on reducing polyp size and alleviating nasal congestion.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.